Content

Tesamorelin vs Sermorelin: What Actually Differs

Creator: Priya Raman, Health Writer
Published: 2026-08-24

Both are growth-hormone-releasing hormone analogues and they are not interchangeable: one is a 44-amino-acid molecule with a current US approval, the other a 29-amino-acid fragment whose branded product left the market in 2008.

Priya Raman, Health Writer August 24, 2026 7 min read

A man sits upright on a bench beside a rack of dumbbells in a quiet daylit gym

The short version

Tesamorelin is the full 44-amino-acid growth-hormone-releasing factor sequence carrying a hexenoyl cap that blocks enzymatic cleavage; sermorelin is the unmodified first 29 amino acids of the same hormone.
Both clear in minutes. Tesamorelin's labelling reports 26 minutes in healthy subjects and 38 minutes in HIV-infected patients after 14 days of daily dosing, against about 4 minutes for GHRH(1-29) on intravenous infusion.
Tesamorelin holds a US approval limited to reducing excess abdominal fat in adults with HIV and lipodystrophy. No sermorelin product currently holds that status — its branded versions were discontinued in 2008 for commercial reasons, not safety ones.
The evidence bases barely overlap: 806 adults in tesamorelin's pooled phase 3 analysis, with visceral fat down 15.4% against placebo at 26 weeks, versus a sermorelin record built mostly in children with growth hormone deficiency.
Both are once-daily subcutaneous injections, because the growth hormone pulse lasts roughly three hours while the peptide itself is long gone.
Through Promise, both are dispensed as compounded medications, which is different from an FDA-approved product: the formulations offered here are not FDA-approved.

Tesamorelin vs sermorelin is a comparison of two growth-hormone-releasing hormone analogues that reach the same pituitary receptor by different routes. Tesamorelin is the full 44-amino-acid growth-hormone-releasing factor sequence carrying a chemical cap that blocks the enzyme which would otherwise cleave it. Sermorelin is the first 29 amino acids of the same hormone, unmodified. Tesamorelin holds a current US approval for one specific population and has a substantial adult trial record. Sermorelin's branded products were discontinued in 2008, and its published evidence sits mostly in children.

Tesamorelin vs sermorelin at a glance

	Tesamorelin	Sermorelin
Structure	44 amino acids — the full growth-hormone-releasing factor sequence	29 amino acids — GHRH(1-29), the shortest fragment with full GHRH activity
Modification	Hexenoyl group on the N-terminal tyrosine, blocking enzymatic cleavage	None; the N-terminus is left exposed
Reported half-life	26 minutes in healthy subjects and 38 minutes in HIV-infected patients after 14 days of daily dosing	About 4 minutes, measured as a disappearance half-time during intravenous infusion
US-approved product	Yes, for one indication	None currently marketed
Approved indication	Reduction of excess abdominal fat in adults with HIV and lipodystrophy	Formerly idiopathic growth hormone deficiency in children, plus a pituitary provocative test
Dosing frequency	Once daily, subcutaneous	Once daily, subcutaneous, given at bedtime in the published trials
Studied in	806 adults with HIV in pooled phase 3 trials, plus later liver-fat trials	Prepubertal children with idiopathic growth hormone deficiency; adults as a diagnostic agent

The structural difference does most of the work

Both molecules bind the same target: the growth-hormone-releasing hormone receptor on the somatotroph cells of the anterior pituitary, which respond by releasing a pulse of the body's own growth hormone. Neither one is growth hormone. That is the shared half of the story.

The difference between tesamorelin and sermorelin begins at the N-terminus. Native growth-hormone-releasing hormone is taken apart quickly in plasma by dipeptidyl peptidase-4, which clips off the first two amino acids and leaves an inactive fragment behind. Sermorelin — GHRH(1-29) — carries that same exposed cleavage site. Tesamorelin instead carries a hexenoyl group, a six-carbon chain with a double bond at position three, attached to the tyrosine at the N-terminal end of the 44-amino-acid sequence, and that cap blocks the clip (EGRIFTA WR prescribing information, DailyMed).

The chemistry is not cosmetic. When that same cleavage site was protected in GHRH(1-29) by a different substitution, metabolic clearance fell by roughly half and the disappearance half-time rose from 4.3 to 6.7 minutes in healthy men (Soule et al., J Clin Endocrinol Metab 1994). Protecting one bond changes how much of an injected dose survives to reach the pituitary.

Half-life, and why the gap is narrower than it sounds

Tesamorelin's original labelling reports a mean elimination half-life of 26 minutes in healthy subjects and 38 minutes in HIV-infected patients after 14 consecutive days of subcutaneous dosing (EGRIFTA prescribing information, FDA). The current formulation's labelling reports about 11 minutes after a single subcutaneous dose in healthy subjects. Sermorelin's published figure is shorter still, at a disappearance half-time of 4.3 minutes on intravenous infusion.

Every one of those numbers is in minutes. Neither compound lingers in circulation for hours, and copy describing tesamorelin as long-acting is comparing 26 minutes with 4 — not a day with an hour.

What lasts longer than either peptide is the response it sets off. After intravenous GHRH(1-29), the peptide was eliminated rapidly while growth hormone levels stayed elevated for about three hours (Wilton et al., Acta Paediatr Suppl 1993). That is why both are given once a day rather than several times a day: the pulse, not the peptide, is the thing being dosed.

What each one was actually studied in

This is where tesamorelin or sermorelin separate most sharply, and it is the row comparison charts usually leave out.

Tesamorelin's evidence is in adults with HIV-associated lipodystrophy. In a 412-patient randomised trial, visceral adipose tissue fell 15.2% on tesamorelin and rose 5.0% on placebo over 26 weeks (Falutz et al., N Engl J Med 2007). A pooled analysis of two phase 3 trials covering 806 patients reported a treatment effect on visceral fat of −15.4% at week 26, with no clinically meaningful differences in glucose measures (Falutz et al., J Clin Endocrinol Metab 2010). A later 61-patient trial in people with HIV and non-alcoholic fatty liver disease reported an absolute reduction in hepatic fat fraction of 4.1% against placebo at 12 months (Stanley et al., Lancet HIV 2019).

Sermorelin's evidence is in children. A review of its clinical record describes sermorelin as the shortest synthetic peptide retaining full GHRH activity, used intravenously at 1 microgram/kg as a provocative test of pituitary function and subcutaneously at 30 micrograms/kg at bedtime in prepubertal children with idiopathic growth hormone deficiency, where height velocity increased over 12 months; the review says this once-daily regimen was not directly compared with somatropin. Transient facial flushing and injection-site pain were the most commonly reported adverse events (Prakash and Goa, BioDrugs 1999).

Tesamorelin has been studied in a randomized trial that included healthy older adults and measured body composition, but that 20-week trial used a lower 1 mg dose and was designed around cognition rather than the outcomes studied in HIV-associated lipodystrophy. That limitation belongs in the comparison rather than being papered over.

Approval status, stated plainly

Tesamorelin is not a general growth hormone drug: its FDA approval covers the reduction of excess abdominal fat in adults with HIV and lipodystrophy, and the labelling states that it is not indicated for weight-loss management. The brand product has been marketed since 2010, and a reformulated version requiring less injection volume was approved in March 2025.

There is no sermorelin product holding FDA approval in the United States today. The branded product, Geref, was approved in 1990 as a diagnostic agent and in 1997 for idiopathic growth hormone deficiency in children with growth failure. Its manufacturer told the agency in 2008 that both were being discontinued and asked for the applications to be withdrawn, which took effect in June 2009. In 2013 the agency determined that neither product was withdrawn from sale for reasons of safety or effectiveness — a commercial exit, formally recorded as one.

Through Promise, both are dispensed as compounded medications, which is different from an FDA-approved product: the formulations offered here are not FDA-approved. Regulatory status is one input into a prescribing decision rather than the whole of it, and a licensed provider may still prescribe a compounded formulation where they judge it appropriate — that decision is between you and your doctor.

Why a GHRH analogue is sometimes paired with a secretagogue

Prescriptions in this category sometimes pair a GHRH analogue with a growth hormone secretagogue, and the reason is receptor-level rather than promotional. Ipamorelin is a pentapeptide that stimulates growth hormone release through the growth-hormone-releasing-peptide receptor — a different receptor from the one tesamorelin and sermorelin bind — and in the study that first characterised it, it did so without the ACTH and cortisol increases seen with earlier compounds of its class (Raun et al., Eur J Endocrinol 1998). A combined preparation therefore acts on two separate pituitary inputs instead of one. Whether that is appropriate for any individual is a prescribing decision, and what ipamorelin does is a separate question from what either GHRH analogue does.

How a prescriber weighs the choice

Indication fit comes first. The question a provider is answering is what problem is being treated, not which peptide is newer — and tesamorelin's controlled evidence sits in a population that most people asking this question are not in.

Contraindications come next, and tesamorelin's labelling is explicit. It is contraindicated where the hypothalamic-pituitary axis has been disrupted by surgery, tumour, irradiation or head trauma, in active malignancy, and in pregnancy. Because raising growth hormone raises IGF-1 by design, glucose is worth watching too; glucose intolerance is a recognised consideration with this class.

Then the practicalities. Both are daily subcutaneous injections that need reconstituting, so neither suits somebody looking for a weekly option. Dose is set by the prescriber against the labelling and the person's own history — no article, chart or seller's protocol substitutes for that.

If the comparison you actually want is sermorelin against a longer-acting analogue rather than against tesamorelin, sermorelin vs CJC-1295 covers that ground. For single-compound background, see what tesamorelin does and the sermorelin benefits picture.

At Promise, a licensed provider reviews every request and prescribes only when it is appropriate for the person asking. Not everyone qualifies.

Common questions

What is the difference between tesamorelin and sermorelin?

Length and stability. Tesamorelin is the full 44-amino-acid growth-hormone-releasing factor sequence with a hexenoyl group attached to its N-terminal tyrosine, which blocks the enzyme that would otherwise cleave it. Sermorelin is the first 29 amino acids of the same hormone, left unmodified. Both bind the same pituitary receptor; tesamorelin's reported half-life is longer and its adult trial record is far larger.

Is sermorelin FDA-approved?

No. FDA-approved sermorelin products existed in the United States — Geref, cleared in 1990 as a diagnostic agent and in 1997 for growth hormone deficiency in children — but the manufacturer discontinued both in 2008 and the applications were withdrawn in 2009. The agency later determined the withdrawal was not for reasons of safety or effectiveness. Sermorelin prescribed today is a compounded preparation and is not FDA-approved.

Is tesamorelin stronger than sermorelin?

Stronger is not the useful comparison. Tesamorelin resists the enzyme that clears growth-hormone-releasing hormone, so more of an injected dose survives to reach the pituitary, and its reported elimination half-life is 26 to 38 minutes against roughly 4 minutes for GHRH(1-29). What that produces in any given person has only been measured in specific trial populations, and not in healthy adults.

Which one would a prescriber choose?

It depends on what is being treated, not on which molecule is newer. Tesamorelin's controlled evidence is in adults with HIV-associated lipodystrophy; sermorelin's is in children with growth hormone deficiency. A provider also screens for contraindications — disruption of the hypothalamic-pituitary axis, active malignancy and pregnancy all rule tesamorelin out — and weighs glucose, cost and whether a daily injection is workable.

How often is each one injected?

Both are once-daily subcutaneous injections in their published protocols. Tesamorelin's labelling specifies a single daily dose into the abdomen; sermorelin was given nightly at bedtime in the paediatric trials. The frequency reflects the biology rather than the peptide's persistence: both clear within minutes, but the growth hormone pulse they trigger lasts around three hours. A prescriber sets the actual dose and schedule.

Why are GHRH analogues sometimes combined with ipamorelin?

Because the two act on different receptors. Tesamorelin and sermorelin bind the growth-hormone-releasing hormone receptor on pituitary somatotrophs. Ipamorelin is a pentapeptide working through the growth-hormone-releasing-peptide receptor, and in the study that characterised it, it released growth hormone without the ACTH and cortisol rises seen with earlier compounds of its class. A combined preparation acts on both inputs.